BUENA, N.J. , June 18, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Raymond James Life Sciences and MedTech Conference June 19, 2019 . The Conference is taking place June 18 th - June 19 th , 2019 at

BUENA, N.J. , May 06, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the first quarter ended March 31, 2019 . First Quarter 2019 Highlights Net revenues of $13.1 million for the first

BUENA, N.J. , May 02, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Monday May 6 th , 2019 to discuss the 1 st  quarter 2019 financial results and business

BUENA, N.J. , April 22, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced that on April 16, 2019 , its development partner has filed the response to the Complete Response Letter (“CRL”) it received on August 30 th ,

BUENA, N.J. , April 12, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today provided commentary on the recent market movements in the price of its stock. “Teligent acknowledges that there have been significant negative

BUENA, N.J. , April 04, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

BUENA, N.J. , March 19, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

BUENA, N.J. , March 18, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2018 . Fourth Quarter 2018 Highlights Net revenues of $16.8 million

BUENA, N.J. , March 15, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at 31 st Annual ROTH Conference March 19, 2019 . The Conference is taking place March 17 th - March 19 th , 2019 at the Ritz Carlton Laguna

BUENA, N.J. , March 14, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.